Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Endometrial cancer
is one of the chief culprits threatening women's lives. Although numerous epidemiological experiments have been carried out into the aetiology of
endometrial cancer
, the cause of the disease has been unclear up to now. In recent years,
PTPN18
, a member of the protein tyrosine phosphatases (PTP) family predicted to be tumour suppressors or oncogenes, has been confirmed to participate in the occurrence and progression of many cancers. Few studies, however, have explained the role in the
endometrial cancer
. So, it caught our attention to explore if
PTPN18
participates in and plays a regulatory role in the proliferation, apoptosis, and metastasis of
endometrial cancer
. In our results, we found that
PTPN18
was overexpressed in
endometrial cancer
tissue compared to paracancerous tissue by immunohistochemistry. Not only that, silencing of
PTPN18
in
endometrial cancer
cell lines (HEC-1-A and HEC-1-B) can significantly impair proliferation detected by CCK8 assay and flow cytometry (FCM) analyses and inhibit the metastasis of
endometrial cancer
cells shown by the scratch test and the Transwell experiment.
PTPN18
knockdown can promote the apoptosis of
endometrial cancer
. In addition, nude mice tumour formation assay confirmed the results in vivo. Although the exact function of
PTPN18
in
endometrial cancer
is unclear, the targeted therapy drugs enhancing
PTPN18
may be considered in the future treatment of
endometrial carcinoma
.
...
PMID:Downregulation of PTPN18 can inhibit proliferation and metastasis and promote apoptosis of endometrial cancer. 3103 93
